The COVID-19 Immunity Task Force embraces the following principles and practices:

  1. Partner in all of its work with the Government of Canada and provincial/territorial governments and their agencies, as well as the research community, public health and healthcare professionals/institutions, and a range of community groups
  2. Identify priority issues related to serologic testing and its application, paying close attention to diverse needs for information across the country
  3. Establish an ethos in which the rigorous gathering and rapidly sharing of data to inform Canadians and to advance the broad public interest over-rides any considerations of personal/group advancement
  4. Mobilize the best science and study designs, recognizing the rapidly evolving state of the science related to serologic testing and to the understanding of SARS-CoV-2 immunity
  5. Establish fair and transparent processes consistent with principles of equity, diversity, and inclusion (EDI) that offer all interested partners across the country an opportunity to participate in the Task Force, while appropriately managing conflicts of interest
  6. Work with partners to ensure protection of privacy in data-gathering and safe handling of any and all biological samples
  7. Collaborate with partners and use existing data- and sample-gathering capacity wherever possible to enhance cost-efficiencies and avoid unnecessary duplication
  8. Provide a central coordination for the Task Force that facilitates rapid development of studies, their effective implementation, and rapid reporting of results to key audiences, including decision makers and interested stakeholders, and the broad Canadian public
  9. Promote ethical and sound participatory practices that engage relevant stakeholders from study design through to dissemination and application of findings
  10. Adhere to best practices regarding any authorship of scientific publications eventually arising from this work, while ensuring that all participants understand that this work is in the public interest, requiring rapid dissemination of reliable and relevant results
  11. Liaise with relevant entities in other countries and with international agencies involved in serologic surveys and studies to understand immunity related to SARS-CoV-2
  12. Communicate the leadership, membership, activities and results of the Task Force with openness and transparency